Odevixibat clinical trials
Also written A4250.
How each study uses odevixibat is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 20 Jul 2021 · BYLVAY · NDA 215498 (FDA, Drugs@FDA)
- European Union
- 16 Jul 2021 · Bylvay · EMEA/H/C/004691 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
10 studies that test it; most in 2018 (3)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2015 | 2 |
| 2018 | 3 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 1
Albireo (5) · Albireo, an Ipsen Company (4) · Sahlgrenska University Hospital (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test odevixibat, phase 3 first.
- Feb 2027Long-term Safety and Efficacy of Odevixibat in Patients With Alagille SyndromePhase 3 · Albireo, an Ipsen Company
Studies
Open first, then newest update. How each study uses odevixibat is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 10
- Long-term Safety and Efficacy of Odevixibat in Patients With Alagille SyndromeActive, not recruitingPhase 3Albireo, an Ipsen CompanyNCT05035030Written as Odevixibat
- An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat in Children With Biliary AtresiaActive, not recruitingPhase 3Albireo, an Ipsen CompanyNCT05426733Written as Odevixibat
- Long Term Safety & Efficacy Study Evaluating The Effect of A4250 in Children With PFICCompletedPhase 3Albireo, an Ipsen CompanyNCT03659916Written as A4250 (odevixibat)
- Efficacy and Safety of Odevixibat in Children With Biliary Atresia Who Have Undergone a Kasai HPE (BOLD)CompletedPhase 3Albireo, an Ipsen CompanyNCT04336722Written as Odevixibat
- This Study Will Investigate the Efficacy and Safety of A4250 in Children With PFIC Types 1 or 2CompletedPhase 3AlbireoNCT03566238Written as A4250 (odevixibat)
- A4250, an IBAT Inhibitor in Pediatric CholestasisCompletedPhase 2AlbireoNCT02630875Written as A4250
- Study of A4250 in Healthy Volunteers Under Fasting, Fed and Sprinkled ConditionsCompletedPhase 1AlbireoNCT03608319Written as A4250
- A Safety and Pharmakokinetic Study of A4250 Alone or in Combination With A3384CompletedPhase 1AlbireoNCT02963077Written as A4250
- Efficacy and Safety of Odevixibat in Patients With Alagille SyndromeCompletedPhase 3AlbireoNCT04674761Written as Odevixibat
- IBAT Inhibitor A4250 for Cholestatic PruritusTerminatedPhase 2Sahlgrenska University HospitalNCT02360852Written as A4250
Codes
What other systems call odevixibat · ClinicalTrials.gg INT001543
- MeSH (NLM) C000713258odevixibatConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 2W150K0UUCODEVIXIBATConfirmed FDA, NLM, Wikidata
- RxNorm 2563966One source FDA
- Wikidata Q76415200odevixibatConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C166598OdevixibatOne source FDA
- DrugBank DB16261One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000713258 | odevixibat | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 2W150K0UUC | ODEVIXIBAT | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2563966 | — | One source FDA |
| Wikidata | Q76415200 | odevixibat | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C166598 | Odevixibat | One source FDA |
| DrugBank | DB16261 | — | One source Wikidata |
Also registered as odevixibat sesquihydrate (UNII Q76KP2H4XW · RxNorm 2563978).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.